The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of getting painfully high inflation under control without a recession.

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

U.S. stock index futures inched lower on Friday, as investors refrained from placing big bets ahead of a crucial inflation ...

Rheumatologists and lab specialists generally support consumers' ability to access tests without a doctor's order, but they remain aware of the possible harms that can come with practice.

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...

Wall Street is poised for a modest rise following encouraging inflation data, which showed the U.S. personal consumption ...

The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...